Table 3.
Toxicity by regimen
| Toxicity | Total (n=200) | TCH (n=47) | AC-TH (n=114) | p-valuea | |||
|---|---|---|---|---|---|---|---|
| Hospitalization | 28 | 14% | 10 | 21% | 14 | 12% | 0.152 |
| Chemotherapy delays/modifications | 68 | 34% | 22 | 47% | 35 | 31% | 0.070 |
| Febrile neutropenia | 13 | 7% | 8 | 17% | 4 | 4% | 0.006 |
| Grade 3/4 Anemia (Hgb <8 g/dl)b | 12 | 6% | 8 | 17% | 3 | 3% | 0.003 |
| Grade 3/4 Thrombocytopenia (platelets < 50K/μl)b | 23 | 12% | 8 | 17% | 5 | 4% | 0.021 |
| Acute Kidney Injury | 7 | 5 | 11% | 2 | 2% | 0.023 | |
| Use of G-CSFc | 124 | 62% | 16 | 34% | 88 | 77% | <0.001 |
Abbreviations: TCH, Taxotere+carboplatin+trastuzumab; AC-TH, adriamycin+cyclophosphamide followed by paclitaxel and trastuzumab; Hgb, hemoglobin; G-CSF, Granulocyte-colony stimulating factor
a
p-value for difference between TCH and AC-TH by Fisher's exact test.
b
Hemoglobin and platelet values were missing in 9 patients, including 4 who received AC-TH and one who received TCH.
c
G-CSF with first cycle; these data were available for all but one patient who received AC followed by trastuzumab.